MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00228-026-04078-8

Медицинская библиотека · European journal of clinical pharmacology · 2026

Mass balance study of [14C]-ABBV-552, a synaptic vesicle glycoprotein 2A positive modulator, in healthy male participants following single oral dose administration.

Miles Nick, McNamee Brian, Soleman Sharif I, Zadikoff Cindy, Boiser Joey, Laplanche Loic, Burton Richard, Shebley Mohamad, Boinpally Ramesh R

СтатьяКлиническое исследование I фазыПеревод пока не подготовлен

Аннотация

PURPOSE: Synaptic density is strongly correlated with cognitive function in many neurological disorders. All synapses contain synaptic vesicle glycoprotein 2 A (SV2A), making it a potential therapeutic target for neurodecline. ABBV-552, a high-affinity positive SV2A modulator, increases neurotransmitter release, improving synaptic efficiency. This Phase 1, open-label, mass balance study examined ABBV-552 safety, pharmacokinetics, metabolism, and elimination.

METHODS

Eight healthy males were orally administered 15 mg [14C]-ABBV-552. Safety was assessed via treatment-emergent adverse event (TEAE), vital sign, electrocardiogram, and laboratory value monitoring. Serial blood, urine, and fecal samples were collected pre-dose, Days 1-14, and daily until discharge. Sample radioactivity was measured with HPLC and metabolites characterized with mass spectrometry.

RESULTS

Eight participants (30-49 years old) received 15 mg [14C]-ABBV-552 (~ 100 µCi) and were included in analyses (3 prematurely withdrew [personal reasons]). All TEAEs were Grade 1 in severity; euphoria (25.0%), dizziness (25.0%), and muscular weakness (12.5%) were deemed possibly-related to ABBV-552. No meaningful changes in laboratory values, vital signs, or ECGs were observed. Mean radioactive recovery was 78.8% (urine: 70.9%, feces: 7.83%), with < 1% parent drug in excreta. Parent and one metabolite (M2, mono-oxidized parent) accounted for 84% and 13%, respectively, of circulating drug-related material. M5, M9, and M33 were most prominent in urine (~ 13%, ~ 17%, ~ 11% of dose, respectively); M2/M36 (coeluted; 1.4% of dose) in feces.

CONCLUSIONS

Orally-administered ABBV-552 was well absorbed and primarily recovered in urine as metabolites. M2 was the only major circulating metabolite. Therefore, ABBV-552 is primarily hepatically metabolized and metabolites are renally eliminated. These findings support further investigation of ABBV-552 in neurodegenerative disorders.

CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov (NCT06278766) Date of registration: 26 February 2024.

Для цитирования: Miles Nick, McNamee Brian, Soleman Sharif I, Zadikoff Cindy, Boiser Joey, Laplanche Loic, Burton Richard, Shebley Mohamad, Boinpally Ramesh R. Mass balance study of [14C]-ABBV-552, a synaptic vesicle glycoprotein 2A positive modulator, in healthy male participants following single oral dose administration.. European journal of clinical pharmacology. 2026. DOI: 10.1007/s00228-026-04078-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.